SLQT News & Events

Reports Q3 revenue $430.9M, consensus $438.93M. SelectQuote Chief Executive Officer Tim Danker remarked, "SelectQuote delivered consistent profit and cash flow for another quarter, despite market shifts for both Medicare Advantage and prescription drugs. We reaffirm our financial outlook for fiscal 2026 driven by operating execution by our agents and continued leverage of our information and technology advantages. Revenue to customer acquisition cost of 6.7X represented a high water mark for the company, and more importantly, signals the value our differentiated healthcare service model provides to policyholders and prescription drug customers. Our goal to drive reliable and consistent profit, and cash flow growth remains priority number one. We believe the improvement to our capital structure to date, combined with the continued maturation of our SelectRx business, positions SelectQuote to materially expand cash flow in the years ahead. We continue to grow our receivables balance, which now stands at nearly $1 billion and grew by nearly $50 million over the past year, including a $14 million positive change in estimate reflective of the durability and dependability of these future cash flows."

SelectQuote announced that the company received a notice from the New York Stock Exchange indicating that the company is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock was less than $1.00 per share over a consecutive 30 trading-day period. The company has notified the NYSE of its intent to cure the stock price deficiency and return to compliance with the continued listing standard. The company can regain compliance at any time within the six-month cure period following receipt of the Notice if, on the last trading day of any calendar month during the cure period, the company's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month.